If you're a Medicare beneficiary, you might reasonably ask why a story about foreign aid belongs in a publication focused on your health insurance. The connection is more direct than it first appears. The Trump administration's sweeping rollback of U.S. foreign assistance — including the effective dissolution of USAID and the cancellation of most global health awards — doesn't only affect mothers and children in sub-Saharan Africa. It sets off a chain of consequences that can eventually reach your pharmacy counter, your Medicare Advantage plan's drug formulary, and the cost of vaccines you receive every year.
To understand the stakes, start with the baseline numbers. In 2024, approximately 4.9 million children under age 5 died globally — more than 13,000 every single day — with the highest concentrations in sub-Saharan Africa. In 2023, roughly 260,000 women died during or following pregnancy and childbirth, with 92% of those deaths occurring in low- and middle-income countries. These are not abstract statistics. They represent the global disease burden that U.S. foreign health programs were specifically designed to reduce. When that infrastructure collapses, disease does not stay contained within national borders, and Americans — including the 67 million enrolled in Medicare — are not insulated from the consequences.
The U.S. government has been involved in global maternal and child health efforts for more than 50 years. Prior to its dissolution in early 2025, USAID served as the lead implementing agency for these programs, coordinating childhood immunization campaigns, nutrition interventions, obstetric care training, and malaria prevention across more than 100 countries. The agency reported helping save more than 9.3 million children and 340,000 women over the past decade alone. That is a measurable return on public health investment — one that also happens to protect Americans from the downstream costs of global disease spread.
On the first day of his second term, President Trump issued executive actions that fundamentally restructured foreign assistance. These included a 90-day review of all foreign aid, a stop-work order that froze payments and services for work already underway, the dissolution of USAID including the reduction of most staff and contractors, and the cancellation of most foreign assistance awards. A waiver was issued to allow life-saving humanitarian assistance to continue, but it was narrowly defined and difficult for program implementers to actually access. Responsibility for remaining global health programs has since been transferred to the State Department — a move that significantly reduces the technical capacity and institutional knowledge that made USAID effective. Legal challenges have been filed, but meaningful legal remedy has been limited.
So what does this mean specifically for Medicare beneficiaries? Start with prescription drugs. Many of the active pharmaceutical ingredients in generic medications — including drugs commonly used by seniors for heart disease, diabetes, and hypertension — are manufactured in countries that receive U.S. foreign assistance. When health systems in those countries destabilize, manufacturing capacity can be affected. More directly, global health research programs historically funded through USAID and affiliated agencies have contributed to the development pipeline for vaccines and treatments that eventually enter the U.S. market and appear on Medicare Part D formularies. Cutting that pipeline does not produce immediate shortages, but it does reduce the long-term supply of affordable generics and new treatments that keep Part D costs manageable.
For Medicare Advantage enrollees, the concern extends to infectious disease preparedness. Medicare Advantage plans — the private insurance alternative to Original Medicare that bundles hospital, medical, and often prescription drug coverage — price their premiums and cost-sharing structures partly based on actuarial projections of what their enrolled population will need. According to CMS.gov data, there were 7,929 Medicare Advantage plans available nationwide in 2025, with average monthly premiums varying significantly by region and plan type. When global disease outbreaks occur — as happened with COVID-19, mpox, and novel influenza strains — they drive up utilization costs across the entire Medicare system, which eventually feeds into premium increases and benefit reductions during the Annual Enrollment Period each fall.
The Annual Enrollment Period runs from October 15 through December 7 each year. This is when Medicare beneficiaries can switch between Original Medicare and Medicare Advantage, change their Part D drug plan, or move between Medicare Advantage plans. The Open Enrollment Period runs January 1 through March 31 and allows a one-time switch from Medicare Advantage back to Original Medicare. Understanding these windows matters because the plan you choose each year reflects the prior year's cost pressures — including any that trace back to global health disruptions. If infectious disease costs rise because preventable outbreaks go unchecked abroad, your 2027 plan options may look meaningfully different from what you have today.
Data Snapshot: According to CMS.gov data, the standard Medicare Part B premium in 2025 was $185.00 per month, up from $174.70 in 2024 — a $10.30 increase in a single year. Part B covers outpatient services including vaccines such as the annual flu shot, pneumococcal vaccines, and COVID-19 boosters, all of which depend on a stable global vaccine supply chain and ongoing research infrastructure. CMS.gov data also shows that approximately 32% of Medicare Advantage enrollees were in plans rated 4 stars or higher in 2025, though that distribution shifts year to year as plans are re-evaluated by CMS. Beneficiaries enrolled in higher-rated plans generally experience more stable benefit structures and better member services — a practical reason to check your plan's star rating at Medicare.gov each fall before the enrollment window closes.
The vaccines you receive at your doctor's office or pharmacy are the downstream product of decades of international health research, much of it coordinated through agencies like USAID and the CDC's Center for Global Health. Cuts to those programs do not eliminate vaccines overnight, but they do reduce the research and manufacturing redundancy that keeps costs stable and supplies reliable. The Fogarty International Center at the National Institutes of Health, which has historically worked in coordination with USAID on infectious disease research, is also facing proposed budget reductions under the broader HHS reorganization — further narrowing the institutional capacity that responds when a disease outbreak begins in a remote region before it becomes a global emergency.
There is also a direct human connection many Medicare beneficiaries may not immediately consider: family. A significant portion of Americans over 65 have children, grandchildren, or other relatives living or working abroad — in Peace Corps postings, missionary work, international business, or military service. The collapse of maternal and child health infrastructure in low- and middle-income countries increases the risk those family members face when they travel or live in regions where preventable diseases are now going unaddressed. Malaria, cholera, measles, and complications from unsafe childbirth do not discriminate based on passport. If a family member returns home ill from a region where disease surveillance has broken down, the health costs of that illness may fall on your household — and potentially on Medicare.
For beneficiaries who want to understand how these macro-level policy shifts might affect their specific coverage, the most practical step is to review your current plan's drug formulary and network during the next Annual Enrollment Period. Pay particular attention to whether your plan covers the vaccines and preventive services you rely on, and whether your Part D plan's formulary still includes the generic medications you take daily. Generic drug prices on Part D plans can shift significantly from year to year — a medication that cost you a $10 copay in 2025 may move to a higher tier in 2026 if your plan renegotiates its formulary. Comparing plans at Medicare.gov's Plan Finder tool, which is updated each October, takes about 20 minutes and can identify meaningful savings.
If you have specific concerns about how federal budget decisions are affecting Medicare's long-term solvency, the Medicare Trustees Report — published annually and available at CMS.gov — provides a detailed actuarial analysis of the program's financial outlook. The 2025 report projected that the Hospital Insurance Trust Fund, which funds Medicare Part A, could face depletion by the mid-2030s without legislative action. Global health spending cuts do not directly affect that trust fund, but they do affect the broader federal health budget environment in which Medicare funding decisions are made. A Congress that has redirected resources away from global health programs is operating in the same fiscal environment where Medicare funding debates take place.
If you are enrolled in a Medicare Advantage plan and want to evaluate whether your current plan is still competitive, look at three specific numbers: the monthly premium, the annual out-of-pocket maximum, and the plan's star rating. In 2025, Medicare Advantage out-of-pocket maximums could reach as high as $9,350 for in-network services, though many plans set lower caps. A plan with a $0 premium but a $9,000 out-of-pocket maximum may cost you far more in a year with significant health needs than a plan with a $50 monthly premium and a $4,500 cap. These comparisons are available for free at Medicare.gov and through your State Health Insurance Assistance Program, known as SHIP, which provides free one-on-one counseling to Medicare beneficiaries. To find your local SHIP counselor, visit shiphelp.org.
The bottom line for Medicare beneficiaries is straightforward: global health policy and domestic Medicare coverage are not separate universes. They are connected through drug supply chains, vaccine development pipelines, infectious disease preparedness, and the federal budget priorities that determine how much money flows into Medicare each year. The dismantling of USAID and the freeze on maternal and child health programs represents a significant shift in how the United States engages with global health — and that shift carries real, if delayed, consequences for the 67 million Americans enrolled in Medicare. Reviewing your plan options each fall during the Annual Enrollment Period, checking your drug formulary for changes, and staying informed about federal health budget decisions are the most practical responses available to you right now.